AI Drug Design Leverage MAbSilico's AI-based antibody design capability to accelerate candidate generation and reduce discovery timelines for biotech and pharma partners seeking faster go/no-go decisions.

Epitope and Developability Target opportunities where customers require in silico epitope mapping, affinity prediction, developability screening and off-target risk assessment to de-risk programs before biological validation.

HDX-MS Collaboration Capitalize on the new AI-driven HDX-MS epitope mapping service to offer integrated computational design plus experimental validation bundles for clients aiming to shorten development timelines.

EU Expansion Position for European biotech and pharma expansion, highlighting ongoing European office growth and local capability in software, data science, and biology to support regional partnerships and regulatory-focused projects.

Strategic Partnerships Pursue co-development and licensing deals with established players (e.g., historical collaboration with Ose Immuno) to expand licenseable AI-generated antibody candidates and broaden go-to-market opportunities.